Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 31c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $6.21 +2.64%
Revenue Growth %: +17.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
CRMT, More
Revenue Growth %: +17.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of $0.14, $0.31 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $43.6 million versus the consensus estimate of $41.54 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Rivian raises 2026 delivery outlook after Q2 results top guidance
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
